Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump ... Montarce said the company can absorb the impact of tariffs within the 2025 guidance and ...

US drug prices are up to five times higher than in other developed nations. Trump's order requires US drug prices to align ...

Eli Lilly (LLY) is among the list of ... much as possible of what we can do to mitigate the impact," Montarce said. Read more: What Trump's tariffs mean for the economy and your wallet Ricks ...

President Trump recently warned big drugmakers that ... the president warned that a "tariff wall" is coming. Although AbbVie, Eli Lilly, and Johnson & Johnson manufacture many of their products ...

Eli Lilly CEO Dave Ricks urged the Trump administration to move fast on ... on tariffs or retaliatory tariffs would have a negative impact on not just Lilly but the entire pharmaceutical industry.

and Eli Lilly CEO David Ricks has personally met with President Trump in recent weeks to discuss the matter. He and CFO Lucas Montarce spoke with Yahoo Finance Thursday about how the company is ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the ...

Johnson & Johnson factored roughly $400 million into its 2025 guidance to account for the impact ... the Trump administration could unleash an even bigger threat than tariffs to AbbVie, Lilly ...